Suma Krishnan - Jul 9, 2025 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
President, R&D, Director, 10%+ Owner
Signature
/s/ Suma M. Krishnan
Stock symbol
KRYS
Transactions as of
Jul 9, 2025
Transactions value $
-$2,122,835
Form type
4
Date filed
7/11/2025, 05:45 PM
Previous filing
Mar 13, 2025
Next filing
Jul 16, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Krishnan Suma President, R&D, Director, 10%+ Owner C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH /s/ Suma M. Krishnan 2025-07-11 0001298711

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Sale -$30K -200 -0.01% $150.14 1.46M Jul 9, 2025 Direct F1, F2
transaction KRYS Common Stock Sale -$976K -6.5K -0.44% $150.23 1.46M Jul 10, 2025 Direct F1, F3
transaction KRYS Common Stock Sale -$45.4K -300 -0.02% $151.39 1.46M Jul 10, 2025 Direct F1, F4
transaction KRYS Common Stock Sale -$30K -200 -0.01% $150.07 1.53M Jul 9, 2025 By Spouse F6, F7, F8
transaction KRYS Common Stock Sale -$995K -6.63K -0.43% $150.22 1.53M Jul 10, 2025 By Spouse F3, F6, F8
transaction KRYS Common Stock Sale -$45.4K -300 -0.02% $151.39 1.53M Jul 10, 2025 By Spouse F4, F6, F8
holding KRYS Common Stock 90K Jul 9, 2025 By SMK Trust
holding KRYS Common Stock 50K Jul 9, 2025 By Krishnan Family Trust F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025 .
F2 The transaction was executed in multiple trades ranging from $150.1200 to $150.1600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $150.0000 to $150.8500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The transaction was executed in three trades of 100 shares each at $151.350, $151.40, and $151.41, respectively. The price reported above reflects the average sale price.
F5 Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
F6 The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025.
F7 The transaction was executed in two trades of 100 shares each at $150 and $150.14, respectively. The price reported above reflects the average sale price.
F8 Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.